A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)

Investigator: Eric Bernicker, MD

Study Coordinator: Syed Muhammad Saad

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03033511

Phone: 281.276.5263

Protocol Number: Pro00019886


The purpose of this study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter trial.
More to Explore
Live Chat Available